Friday 25 September 2020 - 11:51
In Business 40 Years - Since 1980
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
A-2311 Alectinib, Hydrochloride Salt, >99%
Synonyms : [AF802] [CH5424802]
Related Terms : [Alecensa]
- Size
- US $
- €
- £
- ¥
- 25 mg
- 49
- 42
- 38
- 5,200
- In stock
- 50 mg
- 63
- 54
- 49
- 6,600
- In stock
- 100 mg
- 92
- 78
- 72
- 9,700
- In stock
- 200 mg
- 139
- 119
- 109
- 14,700
- In stock
- 250 mg
- 161
- 138
- 126
- 17,000
- In stock
- 500 mg
- 259
- 222
- 203
- 27,300
- In stock
- 1 g
- 378
- 324
- 296
- 39,900
- In stock
- 2 g
- 684
- 586
- 536
- 72,100
- In stock
- 5 g
- 1,240
- 1,063
- 973
- 130,800
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 519.08
- C30H34N4O2HCl
- [1256589-74-8]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO.
- This research compound is the hydrochloride salt form of alectinib; we also offer the free base form of alectinib; please see Cat. No. A-2300, Alectinib Free Base. The free base form and further technical Information will be available on our website shortly. The free base form of alectinib is used for some or all formulations of alectinib for use in humans.
- This product is the hydrochloride salt, whose CAS number is given above. The CAS number of Alectinib, Free Base is 1256580-46-7.
- Related CAS numbers: 1256590-18-7 for the hydrochloride salt, equivalent ratio not specified; 1358953-69-1 for the methanesulfonate salt, equivalent ratio not specified; and 1820744-87-3 for the hydrochloride hydrate salt (1:1:1).
- Another CAS number previously assigned to alectinib, namely 1416163-60-4, has been deleted by CAS and is no longer in use.
- Alectinib is the active ingredient in the drug product sold under the trade name Alecensa®. This drug is currently approved in at least one country for use in patients with anaplastic lymphoma kinase -positive metastatic non-small cell lung cancer. NOTE: THE ALECTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ALECENSA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
